Hormonal
GLP-1 receptor agonists improve cardiovascular outcomes in patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure with preserved ejection fraction (HFpEF), but may increase heart failure hospitalization risk in patients with heart failure with reduced ejection fraction (HFrEF).
If you have heart disease or heart failure, GLP-1 RAs can significantly reduce your risk of major cardiovascular events like heart attack or stroke, especially if you have HFpEF. However, if you have HFrEF (reduced ejection fraction), these drugs may increase your risk of hospitalization, so your doctor will need to carefully weigh the risks and benefits.
SELECT showed that semaglutide 2.4 mg weekly led to a 20% relative risk reduction in major adverse cardiovascular events (MACE)... GLP-1 RAs have demonstrated notable benefits in HFpEF... In FIGHT... failed to demonstrate improvement in functional status... showed a non-significant trend toward increased heart failure hospitalizations in the liraglutide group
Why this rating
Based on large randomized controlled trials (SELECT, STEP-HFpEF, FIGHT) with clear differential outcomes based on phenotype.
Source
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
Lucianne West et al. · Reviews in Cardiovascular Medicine · 2026
DOI 10.31083/rcm44528
More from this paper
- GLP-1 receptor agonists (specifically semaglutide 2.4 mg and tirzepatide) produce significant weight loss (14.9-20.9%) and improve cardiometabolic risk factors in adults with overweight or obesity, regardless of diabetes status.Strong
- GLP-1 receptor agonists provide renal benefits, including reduced albuminuria and slower eGFR decline, in patients with type 2 diabetes and chronic kidney disease, independent of glycemic control.Good
- GLP-1 receptor agonists (semaglutide, tirzepatide, survodutide, retatrutide) promote resolution of metabolic dysfunction-associated steatohepatitis (MASH) and improve liver fibrosis in patients with MASLD/MASH.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →